



Press release |

Regulated information

IBA signs new *Proteus*[®]*ONE* binding term sheet with Proton Partners International

Louvain-La-Neuve, Belgium, 28 June 2016 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a new binding term sheet, containing a significant and immediate down-payment, with Proton Partners International (PPI), to install a *Proteus*[®]*ONE** compact proton therapy solution. This latest *Proteus*[®]*ONE* purchase is part of PPI's strategy to expand its proton therapy network internationally. The location of this center will be disclosed at a later stage.

The term sheet covers delivery of the *Proteus*[®]*ONE* equipment, including Pencil Beam Scanning (PBS) and Cone Beam CT (CBCT) capabilities making it the only compact solution ready for Adaptive Treatment. The term sheet also includes a maintenance agreement. The typical end-user price for a *Proteus*[®]*ONE* system with a maintenance contract is between EUR 35 and 40 million and it is expected that the center will be treating patients in 2018.

This center is the fourth to be built for PPI and will be the 14th installation of IBA's compact single-room proton therapy solution globally. IBA has already sold 42 PT centers worldwide, with this project being the latest to be signed as a result of the framework agreement with Philips that has been in place since September 2014, demonstrating the benefit of this relationship in bringing new international contracts to fruition.

Olivier Legrain, Chief Executive Officer of IBA, commented: "We are delighted that IBA has been selected by PPI to build another new *Proteus*[®]*ONE*. PPI's choice of IBA and our compact solution once again, not only strengthens our world-leading position in proton therapy, but also demonstrates the increasing demand for this cutting edge treatment modality. At present, proton therapy represents only 1% of all radiotherapy treatments, however, studies estimate that more than 17% of patients treated by radiotherapy would benefit from being treated with proton therapy."

Mike Moran, Chief Executive Officer of Proton Partners International Limited, added: "The professional support and responsiveness that IBA has demonstrated throughout our collaborations has resulted in the signing of a new agreement with them. Cancer incidence is rising dramatically, globally, and more innovation is needed to deal with this disease. Our strategy of building a strong international network of proton therapy centers will guarantee high quality treatment throughout our network, enabling ever more patients to benefit from cutting-edge proton therapy."

ENDS

About *Proteus*[®]*ONE*

Proteus[®]*ONE* is the compact intensity modulated proton therapy (IMPT) solution from IBA. It benefits from the latest technologies developed with renowned clinical institutions. *Proteus*[®]*ONE* is smaller, more affordable, easier to install and to operate. It is ultimately easier to finance, making this advanced radiation therapy modality available to more institutions and patients worldwide. *Proteus*[®]*ONE* makes Proton Therapy easy.



Press release |

Regulated information

* *Proteus®ONE is the brand name of a new configuration of the Proteus®235*

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1,300 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange Euronext. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

About Proton Partners International Limited

Proton Partners International is a private limited company, registered in Wales. The company was formed following discussions between Professor Karol Sikora, former head of the World Health Organisation's cancer programme, Professor Sir Chris Evans, the leading life sciences entrepreneur, and Neil Woodford, founding partner of Woodford Investment Management. Institutional and private investors have committed to almost £100m equity finance in the company.

Professor Gordon McVie, Senior Consultant at the European Institute of Oncology, has been appointed chairman, Professor Karol Sikora is Chief Medical Advisor and one of the Founders, Mike Moran has been appointed as the Chief Executive Officer.

For further information please contact:

IBA

Jean-Marc Bothy
Chief Strategy Officer
+32 10 475 890

Investorrelations@iba-group.com

Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890

Communication@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications

Amber Fennell, Matthew Neal, Ivar Milligan
+44 (0) 20 3709 5700

IBA@consilium-comms.com

Rx Communications Group (US)

Melody Carey
+1 917 322 2571

mcarey@RxIR.com